Literature DB >> 24202374

Small nanobody drugs win big backing from pharma.

Sarah C P Williams.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24202374     DOI： 10.1038/nm1113-1355

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura.

Authors:  Filip Callewaert; Jan Roodt; Hans Ulrichts; Thomas Stohr; Walter Janse van Rensburg; Seb Lamprecht; Stefaan Rossenu; Sofie Priem; Wouter Willems; Josefin-Beate Holz
Journal:  Blood       Date:  2012-09-04       Impact factor: 22.113
  1 in total
  10 in total

1.  Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model.

Authors:  Wouter Van Overbeke; Adriaan Verhelle; Inge Everaert; Olivier Zwaenepoel; Joël Vandekerckhove; Claude Cuvelier; Wim Derave; Jan Gettemans
Journal:  Mol Ther       Date:  2014-07-15       Impact factor: 11.454

Review 2.  Are there relevant animal models to set research priorities in LUTD? ICI-RS 2019.

Authors:  Karl-Erik Andersson; Lori Birder; Christopher Chermansky; Russell Chess-Williams; Christopher Fry
Journal:  Neurourol Urodyn       Date:  2020-07       Impact factor: 2.696

3.  Nanobodies as modulators of inflammation: potential applications for acute brain injury.

Authors:  Björn Rissiek; Friedrich Koch-Nolte; Tim Magnus
Journal:  Front Cell Neurosci       Date:  2014-10-21       Impact factor: 5.505

4.  In vitro nanobody discovery for integral membrane protein targets.

Authors:  Rupak Doshi; Beverly R Chen; Cecile Rose T Vibat; Norman Huang; Chang-Wook Lee; Geoffrey Chang
Journal:  Sci Rep       Date:  2014-10-24       Impact factor: 4.379

Review 5.  Bispecific antibodies and their applications.

Authors:  Gaowei Fan; Zujian Wang; Mingju Hao; Jinming Li
Journal:  J Hematol Oncol       Date:  2015-12-21       Impact factor: 17.388

6.  Comparative Studies on Behavioral, Cognitive and Biomolecular Profiling of ICR, C57BL/6 and Its Sub-Strains Suitable for Scopolamine-Induced Amnesic Models.

Authors:  Govindarajan Karthivashan; Shin-Young Park; Joon-Soo Kim; Duk-Yeon Cho; Palanivel Ganesan; Dong-Kug Choi
Journal:  Int J Mol Sci       Date:  2017-08-09       Impact factor: 5.923

7.  Genetic Removal of the CH1 Exon Enables the Production of Heavy Chain-Only IgG in Mice.

Authors:  Tianyi Zhang; Xueqian Cheng; Di Yu; Fuyu Lin; Ning Hou; Xuan Cheng; Shanshan Hao; Jingjing Wei; Li Ma; Yanbin Fu; Yonghe Ma; Liming Ren; Haitang Han; Shuyang Yu; Xiao Yang; Yaofeng Zhao
Journal:  Front Immunol       Date:  2018-09-25       Impact factor: 7.561

8.  Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers.

Authors:  Yohei Kitamura; Nobuhiko Kanaya; Susana Moleirinho; Wanlu Du; Clemens Reinshagen; Nada Attia; Agnieszka Bronisz; Esther Revai Lechtich; Hikaru Sasaki; Joana Liliana Mora; Priscilla Kaliopi Brastianos; Jefferey L Falcone; Aldebaran M Hofer; Arnaldo Franco; Khalid Shah
Journal:  Sci Adv       Date:  2021-03-03       Impact factor: 14.136

Review 9.  Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy.

Authors:  Shuyang Sun; Ziqiang Ding; Xiaomei Yang; Xinyue Zhao; Minlong Zhao; Li Gao; Qu Chen; Shenxia Xie; Aiqun Liu; Shihua Yin; Zhiping Xu; Xiaoling Lu
Journal:  Int J Nanomedicine       Date:  2021-03-22

10.  Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors.

Authors:  Yanni Zhu; Nicole Bassoff; Clemens Reinshagen; Deepak Bhere; Michal O Nowicki; Sean E Lawler; Jérémie Roux; Khalid Shah
Journal:  Sci Rep       Date:  2017-06-01       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.